secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioRestorative Therapies, Inc. (BRTX)
CIK:        0001505497
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001021771-25-000092
Event type: other_material
Sentiment:  positive
Materiality: 0.78
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioRestorative presents Phase 2 data for BRTX-100: >50% improvement in pain/function in >70% of subjects
--------------------------------------------------------------------------------

- Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.
- Over 74% of subjects showed >50% improvement in function (ODI) by week 52; over 72% had >50% pain reduction (VAS).
- No serious adverse events or dose-limiting toxicities reported between 26 and 104 weeks at target dose of 40 million cells.
- Number of evaluated subjects increased from 15 to 36 since last update; FDA requires >30% improvement thresholds.
- CEO Lance Alstodt expressed confidence BRTX-100 can meet or exceed FDA thresholds for function and pain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505497/000102177125000092/0001021771-25-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505497/000102177125000092/brt8k.htm
  HTML page:      https://secwatch.observer/filing/0001021771-25-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer